Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Stockhead on MSN6h
Five ASX healthcare companies poised for game-changing catalystsEBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...
CarExpert.com.au on MSN2h
2026 Cadillac Vistiq: Seven-seat EV detailed, but will it come to Australia?Cadillac is being coy about what vehicles it launches next in Australia, but the three-row Vistiq is shaping up as a distinct ...
The last dates for submission of written comments and counter-comments on the paper have been extended up to November 19 and November 26, respectively ...
Track everything you want to watch and receive e-mail when movies open in theaters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback